JP2015509707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509707A5 JP2015509707A5 JP2014553750A JP2014553750A JP2015509707A5 JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5 JP 2014553750 A JP2014553750 A JP 2014553750A JP 2014553750 A JP2014553750 A JP 2014553750A JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- polypeptide
- length
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 150000001413 amino acids Chemical class 0.000 claims description 72
- 230000002163 immunogen Effects 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 229920001184 polypeptide Polymers 0.000 claims 70
- 108091033319 polynucleotide Proteins 0.000 claims 32
- 102000040430 polynucleotide Human genes 0.000 claims 32
- 239000002157 polynucleotide Substances 0.000 claims 32
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 230000000798 anti-retroviral effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382031.8 | 2012-01-27 | ||
| EP12382031.8A EP2620446A1 (en) | 2012-01-27 | 2012-01-27 | Immunogens for HIV vaccination |
| PCT/EP2013/051596 WO2013110818A2 (en) | 2012-01-27 | 2013-01-28 | Immunogens for hiv vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Division JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509707A JP2015509707A (ja) | 2015-04-02 |
| JP2015509707A5 true JP2015509707A5 (enExample) | 2016-03-17 |
| JP6306514B2 JP6306514B2 (ja) | 2018-04-04 |
Family
ID=47603800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553750A Active JP6306514B2 (ja) | 2012-01-27 | 2013-01-28 | Ｈｉｖワクチン接種のための免疫原 |
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9988425B2 (enExample) |
| EP (3) | EP2620446A1 (enExample) |
| JP (2) | JP6306514B2 (enExample) |
| KR (2) | KR102140778B1 (enExample) |
| CN (2) | CN110372798A (enExample) |
| AU (2) | AU2013213564B2 (enExample) |
| BR (1) | BR112014018396B1 (enExample) |
| CA (1) | CA2862172C (enExample) |
| ES (1) | ES2932407T3 (enExample) |
| IL (2) | IL233771B (enExample) |
| IN (1) | IN2014DN06164A (enExample) |
| MX (2) | MX358711B (enExample) |
| NZ (3) | NZ628756A (enExample) |
| RU (2) | RU2721274C2 (enExample) |
| WO (1) | WO2013110818A2 (enExample) |
| ZA (1) | ZA201405204B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2015140774A1 (en) * | 2014-03-21 | 2015-09-24 | Nutech Ventures | A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| US20220226459A1 (en) * | 2019-05-22 | 2022-07-21 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| EP4417974A1 (en) | 2023-02-17 | 2024-08-21 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Cd33 as a biomarker of hiv control |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US6610476B1 (en) | 1984-08-22 | 2003-08-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of HIV-1 DNA |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5976541A (en) | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
| US5081226A (en) | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| GB8918200D0 (en) | 1989-08-09 | 1989-09-20 | Medical Res Council | The peptide fragments of hiv |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US7319000B1 (en) | 1992-09-16 | 2008-01-15 | Board Of Regents, The University Of Texas System | Compositions and methods for eliciting immune or anti-infective responses |
| AU693098B2 (en) | 1993-06-09 | 1998-06-25 | Connaught Laboratories Limited | Tandem synthetic HIV-1 peptides |
| KR20050052548A (ko) | 1994-12-24 | 2005-06-02 | 캠브리지 유니버시티 테크니칼 서비스 리미티드 | 자궁내막기능 또는 자궁내막기능과 관련된 기능의 개선방법 |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US6093400A (en) | 1996-08-09 | 2000-07-25 | Cel Sci Corporation | Modified HGP-30 peptides, conjugates, compositions and methods of use |
| CA2262432A1 (en) | 1996-08-09 | 1998-02-19 | Viral Technologies, Inc. | Hiv p-17 peptide fragment, compositions containing and methods for producing and using same |
| US6031647A (en) | 1996-10-23 | 2000-02-29 | Nortel Networks Corporation | Stable power control for optical transmission systems |
| US5972339A (en) | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
| US20040106136A1 (en) | 1999-01-25 | 2004-06-03 | Musc Foundation For Research Development | Method for testing drug susceptibility of HIV |
| CN1297932A (zh) * | 1999-11-30 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸 |
| DK1240186T3 (da) * | 1999-12-23 | 2010-05-31 | Medical Res Council | Forbedringer i eller relateret til immunrespons mod HIV |
| FR2803307A1 (fr) * | 1999-12-30 | 2001-07-06 | Centre Nat Rech Scient | Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo |
| US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| CN1312275A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸 |
| EP1278541A1 (en) | 2000-04-28 | 2003-01-29 | The Government of The United States of America, as represented by The Department of Health and Human Services | Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
| ATE318908T1 (de) | 2000-05-18 | 2006-03-15 | Geneart Gmbh | Synthetische gene für gagpol und deren verwendungen |
| AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| EP2302059A1 (en) * | 2000-08-14 | 2011-03-30 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| CU23235A1 (es) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| JP4601956B2 (ja) | 2001-09-20 | 2010-12-22 | グラクソ グループ リミテッド | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
| AUPR842501A0 (en) | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US20050266024A1 (en) | 2002-03-19 | 2005-12-01 | Powdermed Limited | Adjuvant |
| RU2238946C2 (ru) * | 2002-04-22 | 2004-10-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci |
| CN1325512C (zh) | 2002-05-16 | 2007-07-11 | 巴法里安诺迪克有限公司 | Hiv调节/辅助蛋白的融合蛋白 |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| WO2004002415A2 (en) | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| EP1638993A4 (en) | 2003-06-10 | 2007-05-09 | Univ Melbourne | IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
| CA2539325C (en) | 2003-09-17 | 2016-03-22 | Duke University | Consensus/ancestral immunogens |
| EP1678292A4 (en) | 2003-09-18 | 2008-05-07 | Univ Emory | IMPROVED MVA VACCINES |
| AU2004276559A1 (en) * | 2003-09-24 | 2005-04-07 | Oxxon Therapeutics Limited | HIV pharmaccines |
| GB0323840D0 (en) | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
| EP1687022A4 (en) | 2003-11-12 | 2008-02-13 | Medical Res Council | RENTA: HIV IMMUNOGENIC AND ITS APPLICATIONS |
| WO2006010106A2 (en) * | 2004-07-09 | 2006-01-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2006026667A2 (en) | 2004-08-27 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
| US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
| US20060095241A1 (en) | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US20060160070A1 (en) | 2004-10-29 | 2006-07-20 | Microsoft Corporation | Association-based epitome design |
| EP2243788A1 (en) | 2005-02-24 | 2010-10-27 | Medical Research Council | HIVCON: An HIV immunogen and uses thereof |
| WO2007008780A2 (en) * | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| BRPI0504117A (pt) | 2005-09-05 | 2007-05-22 | Fundacao De Amparo A Pesquisa | epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção |
| SG170092A1 (en) | 2006-03-10 | 2011-04-29 | Peptcell Ltd | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
| GB0608368D0 (en) | 2006-04-28 | 2006-06-07 | Isis Innovation | Process for making Oligopeptides |
| EP2023954B1 (en) | 2006-05-19 | 2013-07-17 | Sanofi Pasteur, Inc. | Immunological composition |
| DK2402451T3 (en) | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| WO2008117813A1 (ja) | 2007-03-28 | 2008-10-02 | Hiroshima University | ニワトリ胚性幹細胞およびその評価方法 |
| JP5345135B2 (ja) * | 2007-04-26 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | 昆虫細胞のための合成の発現ベクター |
| WO2009009743A2 (en) * | 2007-07-12 | 2009-01-15 | Institute For Advance Study | Sequence optimization for expression of a foreign gene |
| CA2711145A1 (en) | 2008-01-16 | 2009-07-23 | Opal Therapeutics Pty Ltd | Immunomodulating compositions and uses therefor |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8709775B2 (en) | 2008-08-29 | 2014-04-29 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| PL2358757T3 (pl) | 2008-11-18 | 2019-02-28 | Beth Israel Deaconess Medical Center | Szczepionki antywirusowe o ulepszonej immunogenności komórkowej |
| EP2477651A1 (en) | 2009-09-17 | 2012-07-25 | Sanofi Pasteur Inc. | Immunological compositions for hiv |
| JP2013507107A (ja) * | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| US20130195904A1 (en) | 2010-01-04 | 2013-08-01 | National University Of Singapore | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications |
| EP2638060A2 (en) | 2010-11-10 | 2013-09-18 | Laboratorios Del Dr. Esteve, S.A. | Highly immunogenic hiv p24 sequences |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| US20220226459A1 (en) | 2019-05-22 | 2022-07-21 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
-
2012
- 2012-01-27 EP EP12382031.8A patent/EP2620446A1/en not_active Withdrawn
-
2013
- 2013-01-28 JP JP2014553750A patent/JP6306514B2/ja active Active
- 2013-01-28 EP EP22195110.6A patent/EP4163290A1/en active Pending
- 2013-01-28 CA CA2862172A patent/CA2862172C/en active Active
- 2013-01-28 CN CN201910705866.5A patent/CN110372798A/zh active Pending
- 2013-01-28 AU AU2013213564A patent/AU2013213564B2/en active Active
- 2013-01-28 EP EP13701288.6A patent/EP2807185B1/en active Active
- 2013-01-28 NZ NZ628756A patent/NZ628756A/en unknown
- 2013-01-28 NZ NZ734689A patent/NZ734689A/en unknown
- 2013-01-28 RU RU2018104969A patent/RU2721274C2/ru active
- 2013-01-28 KR KR1020197018840A patent/KR102140778B1/ko active Active
- 2013-01-28 US US14/374,334 patent/US9988425B2/en active Active
- 2013-01-28 IN IN6164DEN2014 patent/IN2014DN06164A/en unknown
- 2013-01-28 CN CN201380006995.6A patent/CN104080800B/zh active Active
- 2013-01-28 RU RU2014135053A patent/RU2648791C2/ru active
- 2013-01-28 BR BR112014018396-1A patent/BR112014018396B1/pt active IP Right Grant
- 2013-01-28 MX MX2014009091A patent/MX358711B/es active IP Right Grant
- 2013-01-28 ES ES13701288T patent/ES2932407T3/es active Active
- 2013-01-28 WO PCT/EP2013/051596 patent/WO2013110818A2/en not_active Ceased
- 2013-01-28 NZ NZ723229A patent/NZ723229A/en unknown
- 2013-01-28 KR KR1020147023946A patent/KR102108149B1/ko active Active
-
2014
- 2014-07-16 ZA ZA2014/05204A patent/ZA201405204B/en unknown
- 2014-07-23 IL IL233771A patent/IL233771B/en active IP Right Grant
- 2014-07-25 MX MX2018010483A patent/MX2018010483A/es unknown
-
2017
- 2017-09-28 US US15/718,635 patent/US10815278B2/en active Active
-
2018
- 2018-03-08 JP JP2018041572A patent/JP6749357B2/ja active Active
- 2018-05-03 US US15/970,216 patent/US11325946B2/en active Active
- 2018-05-10 AU AU2018203264A patent/AU2018203264B2/en active Active
-
2019
- 2019-08-11 IL IL268629A patent/IL268629B/en active IP Right Grant
-
2021
- 2021-04-29 US US17/244,042 patent/US11919926B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162907B2 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| CN104884082B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| JP2008529558A5 (enExample) | ||
| JP2016533332A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| BR112020022393A2 (pt) | composição, vacina compreendendo uma composição, método para produzir uma composição, molécula de ácido nucleico, e, vetor, célula hospedeira, kit compreendendo uma composição, e, vacinas para uso na profilaxia e/ou tratamento de infecção por citomegalovírus e por vírus sincicial respiratório. | |
| JP2018512856A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| US9388225B2 (en) | Modified coiled coil type proteins having improved properties | |
| JP2013532971A5 (enExample) | ||
| JP2013501038A5 (enExample) | ||
| JP2013507907A5 (enExample) | ||
| CN105960412A (zh) | 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒 | |
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| TW200844230A (en) | Signaling peptides | |
| CN117279659A (zh) | 人偏肺病毒疫苗 | |
| JP2016508143A5 (enExample) | ||
| JP2012516140A5 (enExample) | ||
| JP2024522385A5 (enExample) | ||
| JP2014504297A5 (enExample) | ||
| JP2016520534A5 (enExample) | ||
| ES2713962T3 (es) | Vacuna para prevenir la enfermedad de edema porcino | |
| JP2020509770A5 (enExample) |